5.95 0.00 (0.00%)
After hours: 4:09PM EDT
|Bid||5.81 x 1000|
|Ask||6.12 x 800|
|Day's Range||5.80 - 6.10|
|52 Week Range||4.98 - 37.05|
|Beta (3Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
President and CEO of Clovis Oncology Inc (30-Year Financial, Insider Trades) Patrick J Mahaffy (insider trades) bought 50,000 shares of CLVS on 08/16/2019 at an average price of $5.59 a share. Continue reading...
Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
Anyone researching Clovis Oncology, Inc. (NASDAQ:CLVS) might want to consider the historical volatility of the share...
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.40 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...
Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.